

# Na Yao

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9855644/na-yao-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8

papers

15

citations

2

h-index

3

g-index

10

ext. papers

33

ext. citations

2.8

avg, IF

0.48

L-index

#	Paper	IF	Citations
8	Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. <i>International Journal of Hematology</i> , <b>2018</b> , 107, 98-104	2.3	9
7	Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 337-343	1.9	5
6	An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment. <i>Journal of Immunology Research</i> , <b>2021</b> , 2021, 5564568	4.5	1
5	Outcomes of patients treated with SVILE P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study. <i>Cancer Biology and Medicine</i> , <b>2020</b> , 17, 795-804	5.2	0
4	SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. <i>Leukemia Research</i> , <b>2020</b> , 96, 106422	2.7	0
3	Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 863-869	4.9	0
2	Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 19-20	2.2	
1	Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2962-2968	1.9	19